๐Ÿ›๏ธ Verified NIH Record โ€ข Updated 2026-02-12

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) (NCT03767348)

๐Ÿ”ต Active, Not Recruiting Phase2 ๐Ÿ’Š Investigational Drug / Biologic Sponsor: Replimune, Inc.

๐Ÿฉบ Plain-English Summary (8th-Grade Level)

The Phase 2 study is a multicenter, open-label study of RP1 to further investigate safety and to estimate the efficacy of RP1 at the RP2D in combination with nivolumab in patients with Stage IIIb-IV unresectable melanoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, non-melanoma skin cancer (NMSC), and non-small cell lung cancer (NSCLC).

Who can join: Review the eligibility criteria below.

Location: University of Birmingham Alabama โ€” Birmingham, Alabama

๐Ÿ“‹ "Do I Qualify?" โ€” 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria โ†—

๐Ÿ“ All Participating Trial Locations (51 Sites)

  • University of Birmingham Alabama โ€” Birmingham, Alabama
  • Banner MD Anderson Cancer Center โ€” Gilbert, Arizona
  • Mayo Clinic โ€” Phoenix, Arizona
  • Carti Cancer Center โ€” Little Rock, Arkansas
  • UC San Diego โ€” La Jolla, California
  • University of Southern California โ€” Los Angeles, California
  • UCLA โ€” Los Angeles, California
  • University of California, Irvine โ€” Orange, California
  • University of California- San Francisco โ€” San Francisco, California
  • Sylvester Comprehensive Cancer Center- University of Miami โ€” Miami, Florida
  • University of Iowa-Cancer Center Research โ€” Iowa City, Iowa
  • James Graham Brown Cancer Center- University of Louisville โ€” Louisville, Kentucky
  • Mayo Clinic โ€” Rochester, Minnesota
  • New York University Clinical Cancer Center โ€” New York, New York
  • Weill Cornell Medical College โ€” New York, New York
  • University of Rochester Medical Center โ€” Rochester, New York
  • Duke Cancer Center โ€” Durham, North Carolina
  • University of Cincinnati Medical Center โ€” Cincinnati, Ohio
  • Providence Portland Medical Center โ€” Portland, Oregon
  • MUSC Health โ€” Charleston, South Carolina
  • West Cancer Center โ€” Germantown, Tennessee
  • The University of Texas MD Anderson Cancer Center โ€” Houston, Texas
  • Eccles Outpatient Care Center- Oncology Clinical Trials โ€” Murray, Utah
  • Intermountain Cancer Center- Saint George Cancer Center โ€” St. George, Utah
  • Seattle Cancer Care Alliance- University of Washington โ€” Seattle, Washington

๐Ÿ’ฐ Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
๐Ÿ›๏ธ View Official NIH Record โ†—